Contents, Vol. 49, No. 4, 1992

Ondansetron - A New Concept in Anti-Emetic Therapy
Satellite Symposium held during Guest Editors
the Sixth European Conference on J. Smyth, Edinburgh
Clinical Oncology and Cancer K. Cunningham, Greenford
Nursing, October 27-31, 1991, Florence, Italy
24 figures and 10 tables, 1992
KARGER
S. Karger
Medical and Scientific Publishers Basel ■ Freiburg • Paris • London New York • New Delhi •
Bangkok Singapore • Tokyo • Sydney

Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage
set forth in this text are in accord with current recommendations and practice at the time of
publication. However, in view of ongoing research, changes in government regulations, and the
constant flow of information relating to drug therapy and drug reactions, the reader is urged to
check the package insert for each drug for any change in indications and dosage and for added
warnings and precautions. This is particularly important when the recommended agent is a new
and/or infrequently employed drug.
All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any
form or by any means, electronic or mechanical, including photocopying, recording,
microcopying, or by any information storage and retrieval system, without permission in writing
from the publisher or, in the case of photocopying, direct payment of a specified fee to the
Copyright Clearance Center (see ‘Information for Readers and Subscribers’).
© Copyright 1992 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland) Printed in
Switzerland on acid-free paper by Graphische Anstalt Schiller AG, Biel ISBN 3-805 5-5656-X
258

Contents

Smyth, J.
Introduction
261
Tyers, M.B.; Freeman, A.J.
Mechanism of the Anti-Emetic Activity of 5-HT3 Receptor Antagonists
263
Olver, I.N.
Methodology in Anti-Emetic Trials
269
Brown, G.W.; Paes, D.; Bryson, J.; Freeman, AJ.
The Effectiveness of a Single Intravenous Dose of Ondansetron
273
Jurgens, H.; McQuade, B.
Ondansetron as Prophylaxis for Chemotherapy and Radiotherapy-Induced Emesis in Children
279
Chairman: Professor J. Smyth
Panel Discussion 1
286
Kaasa, S.
Measurement of Quality of Life in Clinical Trials
288
Ondansetron Compared with Metoclopramide in the Control of Emesis and Quality of Life during Repeated Chemotherapy for Breast Cancer
Depierre, A.; Lebeau, B.; d’Allens, H.; A Comparison of Ondansetron with Alizapride plus Methylprednisolone in the Control of Cisplatin-Induced Emesis
Ondansetron Study
Fitch, M.I. Managing Treatment-Induced Emesis: A Nursing Perspective
312
Chairman: Professor M. Tonato Panel Discussion 2 317
Smyth, J. Development of Ondansetron. Summary
319